Feasibility of different doses of dexmedetomidine required to prevent sufentanil-induced cough during anesthesia induction
10.3760/cma.j.issn.0254-1416.2011.05.005
- VernacularTitle:不同剂量右美托咪啶预防舒芬太尼诱发患者全麻诱导期间呛咳反应的可行性
- Author:
Shen SUN
;
Shaoqiang HUANG
- Publication Type:Journal Article
- Keywords:
Dexmedetomidine;
Sufentanil;
Cough
- From:
Chinese Journal of Anesthesiology
2011;31(5):539-541
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the feasibility of different doses of dexmedetomidine required to prevent sufentanil-induced cough during anesthesia induction. Methods Two hundred and forty ASA Ⅰ or Ⅱ patients, aged 18-55 yr, weighing 45-78 kg, undergoing elective gynecological operations under general anaesthesia, were randomly divided into 4 groups ( n = 60 each) : Ⅰ -Ⅳ groups. Ⅱ -Ⅳ groups received iv infusion of dexmedetomidine 0.10, 0.25 and 0.50 fig/kg at a rate of 0.05 μg·kg-1·min-1 respectively before anesthesia induction. Anesthesia was induced with target-controlled infusion of propofol (target effect-site concentration 5 μg/ml) , when the BIS value reached 55, iv sufentanil 0.5 fig/kg was injected over 3 s. The occurrence and degree of cough were recorded within 1 min after sufentanil injection. Tracheal intubation was facilitated with succinylcholine 1-2 mg/kg after the observation. The adverse cardiovascular events (severe sinus bradycardia, hypotension) were also record ed from the start of dexmedetomidine infusion to 1 min after intubation. Results The incidences of cough were 25 % , 7 % , 7 % and 5 % , incidences of severe sinus bradycardia 0, 3 % , 15 % and 25 % , and incidences of hypotension 5% , 7% , 8% and 8% in Ⅰ - Ⅳ groups respectively. Compared with group Ⅰ , the incidences of cough were significantly decreased in Ⅱ - Ⅳ groups, while the incidences of severe sinus bradycardia increased in Ⅲ -Ⅳ groups (P ＜ 0.01) . There was no significant difference in the incidences of cough among Ⅱ - Ⅲ groups and in the degree of cough among the four groups (P ＞ 0.05). Conclusion Intravenous dexmedetomidine 0.10 μg/kg can be used to prevent sufentanil-induced cough during anesthesia induction.
